All data tables are provided in the paper.

Introduction {#sec001}
============

Chronic obstructive pulmonary disease (COPD) is a debilitating disease that is characterized by reduced lung function, breathlessness, decreased productivity, and poor quality of life \[[@pone.0158843.ref001]\]. Currently, COPD is the only major cause of mortality with a rising death rate and it is estimated that by 2030 COPD will become the fourth leading cause of death worldwide \[[@pone.0158843.ref002],[@pone.0158843.ref003]\]. The natural history of COPD is often marked by periodic exacerbations in which symptoms of breathlessness and sputum production worsen acutely, resulting in emergency room visits and hospitalizations \[[@pone.0158843.ref001],[@pone.0158843.ref004],[@pone.0158843.ref005]\]. In Canada, acute exacerbations of COPD (AECOPD) account for the highest rate of hospital admissions and repeat hospitalizations \[[@pone.0158843.ref006]\], with an estimated economic burden amounting to \$4.5 billion dollars each year in direct and indirect costs \[[@pone.0158843.ref007]\].

Owing to their heterogeneity and the lack of available diagnostic laboratory tests, AECOPD are often diagnosed based on clinical gestalt, which is subjective and variable within and across physicians. Forced expiratory volume in the first second of expiration (FEV1) has conventionally been used to guide therapy in stable COPD; however, it is a poor indicator of a patient's exacerbation status \[[@pone.0158843.ref001]\]. Instead, biomarkers are biological molecules that may better reflect disease activity and fluctuate in accordance with disease state, while representing biologically plausible pathways \[[@pone.0158843.ref008]\]. Theoretically, as readily available point-of-care tests that can supplement clinical data, they could provide a more objective determination of a patient's health status before, during, and after an AECOPD event \[[@pone.0158843.ref009]--[@pone.0158843.ref011]\]. While levels of these biomarkers may be altered when comparing stable COPD patients to normal controls \[[@pone.0158843.ref012]\], further disturbances may be observed in the acute setting of an exacerbation. Biomarkers could further allow physicians to provide personalized care for each patient by tailoring targeted therapies based on biomarker levels, thus avoiding unnecessary side effects of prolonged exposure to drugs or conversely incompletely treating an AECOPD. For instance, certain biomarkers could potentially point to a bacterial or viral origin, thus guiding appropriate therapy \[[@pone.0158843.ref013]\].

There have been numerous articles published over the past decade, which have focused on the discovery and assessment of biomarkers in relation to AECOPD \[[@pone.0158843.ref014]\]. Similarly, there have been a wide variety of sample types that have been collected for this purpose including exhaled breath condensate, sputum, nasal wash, blood, bronchoalveolar lavage, and lung biopsies. In this review, we have focused our attention on blood-based biomarkers to diagnose exacerbations. This type of sample has clear advantages that make clinical translation facile including non-invasiveness, ease of collection, widespread availability of laboratories that can procure and process these samples, and the ability to standardize measurements for most assays. The aims of this systematic review are to determine which plasma or serum molecules have been evaluated (and published) as possible biomarkers to diagnose AECOPD and to ascertain the quality of these publications with the view of determining which molecules, if any, have the greatest potential for clinical translation.

Methods {#sec002}
=======

Study population {#sec003}
----------------

Our population of interest was defined as COPD patients of any age and gender, who had experienced exacerbations, and as a consequence, required medical attention and admission to a hospital for treatment. We included studies that examined patients longitudinally (i.e. onset of AECOPD versus convalescence), and also those that were cross-sectional (i.e. AECOPD versus stable COPD). Studies that focused on exacerbation biomarkers to guide therapeutic treatments were excluded. The biomarkers, which we subsequently reviewed after study selection, were categorized and described in terms of their use in the diagnosis of AECOPD onset.

Literature search and article selection {#sec004}
---------------------------------------

We employed our search strategy in accordance with the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) guidelines ([S1 PRISMA Checklist](#pone.0158843.s001){ref-type="supplementary-material"}), as well as PRISMA for abstracts \[[@pone.0158843.ref015],[@pone.0158843.ref016]\]. We searched articles in MEDLINE (1966--2015), EMBASE (1980--2015), CINAHL (1982--2015), and Cochrane databases by using specific Medical Subject Headings (MeSH) terms. We used Elsevier ScienceDirect as an additional source. The MeSH terms included a combination of: chronic obstructive pulmonary disease or COPD, exacerbations, acute exacerbation, or AECOPD, biomarkers or biological markers, diagnosis or diagnostic, and blood or serum or plasma (a detailed list of MeSH terms is provided in [S1 Table](#pone.0158843.s002){ref-type="supplementary-material"}). Two authors (YWRC and JML) independently screened the titles and abstracts based on the articles' relevance to our MeSH terms, with disagreements resolved by iteration and consensus. Primary articles that were published in English, focused on human subjects (animal studies were excluded), and performed analysis on blood specimens were retained. Entries of review articles, conference abstracts, book chapters, editorials, or original articles that performed biomarker assessments on sputum samples, or breath condensate were excluded. References from selected articles were also reviewed to ensure the inclusion of all relevant articles.

Data extraction and study quality assessment {#sec005}
--------------------------------------------

To assess the quality of publications reporting biomarkers, we first screened the 59 relevant original papers for the two important analytic components of biomarker studies, as recommended by Sin and colleagues \[[@pone.0158843.ref017]\]. These components included: 1) the use of receiver operating characteristics (ROC) area-under-the curve (AUC) statistics or equivalent in reporting the performance of the biomarker as a diagnostic tool for AECOPD, and 2) the reporting of biomarker findings in a replication cohort or sub-cohort of the parent study. We additionally used the Guidelines for the REporting of Tumor MARKer Studies (REMARK) to rank these selected publications (see [S2 Table](#pone.0158843.s003){ref-type="supplementary-material"} for a detailed REMARK checklist) \[[@pone.0158843.ref018]\]. Because REMARK was created for oncology studies, we modified the criteria to enable use for AECOPD (resulting in a modified or mREMARK score). For instance, where the guidelines mentioned recommendations pertaining to tumor biomarkers (in points 13 and 15 of [S2 Table](#pone.0158843.s003){ref-type="supplementary-material"}), we simply replaced these terms with \"AECOPD biomarkers\". In cases where the guidelines referred to standard prognostic variables (in points 14 and 17 of [S2 Table](#pone.0158843.s003){ref-type="supplementary-material"}), we replaced this concept with lung function measurements, which have significant prognostic value in COPD. A collection of mREMARK scores were then collated and ranked. Higher mREMARK scores were considered reflective of a higher quality study, with the maximum achievable mREMARK score being 20.

Results {#sec006}
=======

Search results {#sec007}
--------------

The initial search revealed a total of 2,732 studies, of which 111 were duplicate articles (see [Fig 1](#pone.0158843.g001){ref-type="fig"}). We also excluded 2,362 other articles by screening titles and abstracts of these articles because they were not relevant to this analysis, leaving 270 articles eligible for full-text review. Among these articles, 211 articles were excluded for reasons that are outlined in [Fig 1](#pone.0158843.g001){ref-type="fig"}. In total, 59 studies were included in the qualitative analysis. A flow diagram of study screening and selection is shown in [Fig 1](#pone.0158843.g001){ref-type="fig"}.

![PRISMA flow diagram of study screening and selection.\
PRISMA flow diagram used in study selection and screening. 59 studies were included for review whereas the rest of the studies were excluded.](pone.0158843.g001){#pone.0158843.g001}

Study characteristics {#sec008}
---------------------

The study characteristics are displayed in [Table 1](#pone.0158843.t001){ref-type="table"} and the patient characteristics are listed in [S3 Table](#pone.0158843.s004){ref-type="supplementary-material"}. The definitions used by all of the studies pertaining to COPD diagnosis, AECOPD, and stable COPD are listed in [S4 Table](#pone.0158843.s005){ref-type="supplementary-material"}. The majority of the studies (53 out of 59) defined COPD diagnosis based on the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria (FEV1/FVC \<70%), and a bronchodilator effect of \<12% in either the FEV1 or FVC \[[@pone.0158843.ref001]\]. 33 out of 59 studies defined an AECOPD based on worsening of symptoms including dyspnea, cough, or sputum production, which led to the intensification in the use of maintenance medications and/or institution of "rescue" medications \[[@pone.0158843.ref001],[@pone.0158843.ref005]\]. Definitions of stable COPD were highly variable among the 59 studies, with duration free of exacerbation ranging from 3 weeks to 3 months (see [S4 Table](#pone.0158843.s005){ref-type="supplementary-material"}). The majority of the studies (12 out of 59) defined stable COPD as being free of exacerbation in the preceding 4 weeks.

10.1371/journal.pone.0158843.t001

###### Study characteristics of 59 publications included in the review arranged by the latest published year.
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  **Reference**                                           **Year**   **Country**   **Single or Multi-centre**   **Biomarkers Tested**                                                                                                                                                                          **Cross-Sectional Assessment**   **Longitudinal Assessment**
  ------------------------------------------------------- ---------- ------------- ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- -----------------------------
  Andelid, K., et al. \[[@pone.0158843.ref019]\]          2015       Sweden        S                            CRP, MPO, Neutrophil Elastase, WBC                                                                                                                                                             Yes                              Yes
  Gumus, A., et al. \[[@pone.0158843.ref020]\]            2015       Turkey        S                            CRP, fibrinogen, SuPAR                                                                                                                                                                         Yes                              Yes
  Chang, C., Yao, W. \[[@pone.0158843.ref021]\]           2014       China         S                            CRP, IL-6                                                                                                                                                                                      No                               Yes
  Chang, C., et al. \[[@pone.0158843.ref022]\]            2014       China         S                            CRP, IL-6, WBC                                                                                                                                                                                 No                               Yes
  Fattouh, M. Alkady, O. \[[@pone.0158843.ref023]\]       2014       Egypt         S                            CRP, Fibrinogen, WBC                                                                                                                                                                           Yes                              Yes
  Johansson, S.L., et al. \[[@pone.0158843.ref024]\]      2014       Denmark       M                            CRP, MFAP4, SP-D, WBC                                                                                                                                                                          Yes                              Yes
  Labib, S., et al. \[[@pone.0158843.ref025]\]            2014       Egypt         S                            Desmosine                                                                                                                                                                                      Yes                              Yes
  Lee, S.J., et al. \[[@pone.0158843.ref026]\]            2014       Korea         S                            Osteopontin                                                                                                                                                                                    Yes                              Yes
  Liu, H.C., et al. \[[@pone.0158843.ref027]\]            2014       Taiwan        S                            IL-8, IL-17                                                                                                                                                                                    Yes                              No
  Liu, Y., et al. \[[@pone.0158843.ref028]\]              2014       China         S                            CD34+ cells, CRP, MMP-9, NT-proBNP                                                                                                                                                             Yes                              No
  Meng, D.Q., et al. \[[@pone.0158843.ref029]\]           2014       China         S                            Adrenomedullin, CRP, WBC                                                                                                                                                                       Yes                              Yes
  Nikolakopoulou, S., et al. \[[@pone.0158843.ref030]\]   2014       Greece        S                            Angiopoietin-2, CRP                                                                                                                                                                            No                               Yes
  Nishimura, K., et al. \[[@pone.0158843.ref031]\]        2014       Japan         S                            BNP                                                                                                                                                                                            Yes                              Yes
  Omar, M.M., et al. \[[@pone.0158843.ref032]\]           2014       Egypt         S                            Adiponectin                                                                                                                                                                                    Yes                              Yes
  Oraby, S.S., et al. \[[@pone.0158843.ref033]\]          2014       Egypt         S                            Adiponectin                                                                                                                                                                                    Yes                              No
  Urban, M.H., et al. \[[@pone.0158843.ref034]\]          2014       Austria       S                            sRAGE                                                                                                                                                                                          No                               Yes
  Zhang, Y., et al. \[[@pone.0158843.ref035]\]            2014       China         S                            CRP, Fibrinogen, HMGB1, sRAGE                                                                                                                                                                  No                               Yes
  Zhao, Y.F., et al. \[[@pone.0158843.ref036]\]           2014       China         S                            Copeptin, CRP, Procalcitonin                                                                                                                                                                   No                               Yes
  Adnan, A.M., et al. \[[@pone.0158843.ref037]\]          2013       Syria         S                            ECP, Eotaxin/CCL11, IL-8                                                                                                                                                                       Yes                              No
  Carter, R.I., et al. \[[@pone.0158843.ref038]\]         2013       UK            S                            Aα-Val^360^                                                                                                                                                                                    No                               Yes
  Gao, P., et al. \[[@pone.0158843.ref039]\]              2013       China         S                            CRP, IL-6, MMP-9, Serum Amyloid-A                                                                                                                                                              Yes                              No
  Jin, Q., et al. \[[@pone.0158843.ref040]\]              2013       China         S                            RBP4                                                                                                                                                                                           Yes                              No
  Mohamed, N.A., et al. \[[@pone.0158843.ref041]\]        2013       Egypt         S                            Adiponectin, CRP, IL-6, IL-8, TNF-α                                                                                                                                                            Yes                              No
  Patel, A.R.C., et al. \[[@pone.0158843.ref042]\]        2013       UK            M                            CRP, fibrinogen, NT-proBNP, Troponin T                                                                                                                                                         No                               Yes
  Scherr, A., et al. \[[@pone.0158843.ref043]\]           2013       Switzerland   S                            Pancreatic stone protein/regenerating protein                                                                                                                                                  Yes                              No
  Shoukry, A., et al. \[[@pone.0158843.ref044]\]          2013       Egypt         S                            IL-6, TNF-α, Thyroid hormone T3, T4, TSH                                                                                                                                                       Yes                              No
  Stanojkovic, I., et al. \[[@pone.0158843.ref045]\]      2013       Serbia        S                            Beta-crosslaps, CRP, MMP-9, TIMP-1                                                                                                                                                             Yes                              Yes
  Chen, H., et al. \[[@pone.0158843.ref046]\]             2012       China         S                            507 inflammatory mediators                                                                                                                                                                     Yes                              No
  Falsey, A.R., et al. \[[@pone.0158843.ref047]\]         2012       USA           S                            Procalcitonin                                                                                                                                                                                  Yes                              Yes
  Huang, J., et al. \[[@pone.0158843.ref048]\]            2012       UK            M                            Desmosine                                                                                                                                                                                      Yes                              No
  Ju, C.R., et al. \[[@pone.0158843.ref049]\]             2012       China         S                            CRP, SP-D                                                                                                                                                                                      Yes                              Yes
  Koczulla, A.R., et al. \[[@pone.0158843.ref050]\]       2012       Germany       S                            Alpha-1 antitrypsin, CRP, Procalcitonin, WBC                                                                                                                                                   Yes                              No
  Kwiatkowska, S., et al. \[[@pone.0158843.ref051]\]      2012       Poland        S                            MMP-9, TIMP-1                                                                                                                                                                                  Yes                              Yes
  Marcun, R., et al. \[[@pone.0158843.ref052]\]           2012       Slovenia      S                            NT-proBNP, Troponin T                                                                                                                                                                          No                               Yes
  Mohamed, K.H., et al. \[[@pone.0158843.ref053]\]        2012       Egypt         S                            CRP, ESR, Procalcitonin, WBC                                                                                                                                                                   Yes                              No
  Pazarli, A.C., et al. \[[@pone.0158843.ref054]\]        2012       Turkey        S                            CRP, ESR, Procalcitonin, WBC                                                                                                                                                                   Yes                              No
  Rohde, G., et al. \[[@pone.0158843.ref055]\]            2012       Germany       S                            sTREM-1                                                                                                                                                                                        Yes                              Yes
  Shaker, A., et al. \[[@pone.0158843.ref056]\]           2012       Egypt         S                            FSH, IGF-1, LH, Testosterone                                                                                                                                                                   Yes                              Yes
  Yerkovich, S.T., et al. \[[@pone.0158843.ref057]\]      2012       Australia     S                            Anti-VP1 IgG~1~, IL-21                                                                                                                                                                         Yes                              No
  Bafadhel, M., et al. \[[@pone.0158843.ref013]\]         2011       UK            S                            24 biomarkers (including CCL4, CCL17, CRP, CXCL11, ECP, Eosinophil % count, IFNγ, IL-5, IL-6, IP-10, Neopterin, Procalcitonin, Serum Amyloid-A, SP-D, TNFR1, TNFR2)                            No                               Yes
  Chen, H., et al. \[[@pone.0158843.ref058]\]             2011       China         S                            40 inflammatory mediators (including betacellulin, CCL17, CCL22, CCL23/MPIF-1, CCL25, CCL27, CCL28, CXCL11, IL-9, MCP-3, MCP-4, osteopontin)                                                   Yes                              Yes
  Lacoma, A., et al. \[[@pone.0158843.ref059]\]           2011       Spain         M                            MR-proANP                                                                                                                                                                                      Yes                              Yes
  Lacoma, A., et al. \[[@pone.0158843.ref060]\]           2011       Spain         M                            CRP, Neopterin, Procalcitonin                                                                                                                                                                  Yes                              Yes
  Lim, S.C., et al. \[[@pone.0158843.ref061]\]            2011       Korea         S                            IL-6, IL-8, TNF-α, T-Lymphocyte Apoptosis                                                                                                                                                      Yes                              No
  Markoulaki, D., et al. \[[@pone.0158843.ref062]\]       2011       Greece        M                            CRP, EPO, Fibrinogen, Hgb, IL-6, TNF-α                                                                                                                                                         No                               Yes
  Krommidas, G., et al. \[[@pone.0158843.ref063]\]        2010       Greece        M                            Adiponectin, CRP, IL-6, Leptin, TNF-α                                                                                                                                                          No                               Yes
  Quint, J.K., et al. \[[@pone.0158843.ref064]\]          2010       UK            M                            CRP, IL-6, IP-10                                                                                                                                                                               Yes                              Yes
  Koutsokera, A., et al. \[[@pone.0158843.ref065]\]       2009       Greece        S                            CRP, Fibrinogen, IL-6, Serum Amyloid-A, TNF-α                                                                                                                                                  No                               Yes
  Kythreotis, P., et al. \[[@pone.0158843.ref066]\]       2009       Greece        S                            IGF-1, IL-1β, IL-6, IL-8, Leptin, TNF-α                                                                                                                                                        Yes                              Yes
  Shakoori, T.A., et al. \[[@pone.0158843.ref067]\]       2009       Parkistan     S                            SP-D                                                                                                                                                                                           Yes                              No
  Karadag, F., et al. \[[@pone.0158843.ref068]\]          2008       Turkey        S                            IL-6, NO, TNF-α                                                                                                                                                                                Yes                              Yes
  Stolz, D., et al. \[[@pone.0158843.ref069]\]            2008       Switzerland   S                            CRP, BNP, Procalcitonin                                                                                                                                                                        No                               Yes
  Groenewegen, K.H., et al. \[[@pone.0158843.ref070]\]    2007       Netherlands   S                            BPI, IL-6, sIL-1RII, sTNFR55, sTNFR75, TEAC                                                                                                                                                    Yes                              Yes
  Perera, W. R., et al. \[[@pone.0158843.ref071]\]        2007       UK            S                            CRP, IL-6                                                                                                                                                                                      No                               Yes
  Pinto-Plata, V.M., et al. \[[@pone.0158843.ref072]\]    2007       USA           S                            IL-6, IL-8, LTB4, SLPI, TNF-α                                                                                                                                                                  No                               Yes
  Hurst, J.R., et al. \[[@pone.0158843.ref073]\]          2006       UK            Multi Centre                 36 biomarkers (including Adiponectin, CRP, CCL4, CCL5, CCL23/MPIF-1, Eotaxin-2, IFNγ, IL-1Ra, IL-6, IL-8, IL-17, IP-10, MCP-1, MMP-9, MPO, PARC/CCL18, sICAM-1, TGF-α, TIMP-1, TNFR1, TNFR2)   No                               Yes
  Phua, J., et al. \[[@pone.0158843.ref074]\]             2006       Spain         S                            sTREM-1                                                                                                                                                                                        Yes                              No
  Roland, M., et al. \[[@pone.0158843.ref075]\]           2001       UK            S                            Endothelin-1                                                                                                                                                                                   No                               Yes
  Fiorini, G., et al. \[[@pone.0158843.ref076]\]          2000       Italy         S                            ECP, IgE, MPO                                                                                                                                                                                  Yes                              No

Note: For studies that included more than 10 biomarkers, not all markers are listed. Abbreviations: S = S, M = multi centre. **Biomarker abbreviations: Aα-Val**^**360**^ **= fibrinogen cleavage product, Anti-VP1 IgG**~**1**~ **= immunoglobulin G1 antibody against viral protein 1, BNP = brain natriuretic peptide, BPI = bactericidal permeability increasing protein, CD = cluster of differentiation, CCL = chemokine C-C motif ligand, CXCL = chemokine C-X-C motif ligand, ECP = eosinophil cationic protein, EPO = erythropoietin, ESR = erythrocyte sedimentation rate, FE = frequent exacerbators, FSH = follicle stimulating hormone, GPx = erythrocytic glutathione peroxidase, Hgb, = hemoglobin, HMGB = high mobility group box, IFN = interferon, IG = immunoglobulin, IGF = insulin-like growth factor, IL = interleukin, IP = interferon-γ inducible protein, LH = luteinizing hormone, LTB4 = leukotriene B4, MCP = monocyte chemoattractant protein, MFAP = microfibrillar associated protein, MMP = matrix metallopeptidase, MPIF = myeloid progenitor inhibitory factor, MPO = myeloperoxidase, MR-proANP = Mid-regional prohormone of atrial natriuretic peptide, NE = non-exacerbators, NO = nitric oxide, NT-proBNP = amino-terminal of the prohormone of brain natriuretic peptide, PARC = pulmonary and activation-regulated chemokine, RBP = retinol-binding proteins, sICAM = soluble intercellular adhesion molecule, sIL-1R = soluble interleukin 1 receptor, SLPI = secretory leukocyte protease inhibitor, SP = surfactant protein, sTNFR = soluble tumor necrosis factor receptors, sRAGE = soluble receptor for advanced glycation end-products, sTREM = soluble triggering receptor expressed on myeloid cells, suPAR = soluble urokinase-type plasminogen activator receptor, TEAC = Trolox equivalent antioxidant capacity, TGF = transforming growth factor, TIMP = tissue inhibitors of metalloproteinase, TNF = tumor necrosis factor, T3 = Triiodothyronine, T4 = thyroxine, TSH = thyroid stimulating hormone, and WBC = white blood cell.**

41 studies evaluated biomarkers longitudinally in the same patients at onset of and recovery from AECOPD. 42 studies evaluated biomarkers cross-sectionally between patients with AECOPD and stable COPD patients, and/or healthy controls. Approximately half of the studies included in the review were performed in Europe (47%), with the United Kingdom being the most prevalent location. Most of the studies were single-centre based (86%) and all were prospective in design. 81% of the studies had a relatively small study size (defined as less than 100 exacerbating patients). The total number of patients included in the 59 studies was 5,431, with a range of 9 to 333 COPD patients per study. Patients were mostly males, and the mean age of all COPD participants were 64 years with a mean FEV1% of approximately 47%.

Biomarkers for the diagnosis of AECOPD {#sec009}
--------------------------------------

In total, 134 distinct biomarkers were measured, with one additional study measuring 507 inflammatory mediators using an antibody microarray \[[@pone.0158843.ref046]\]. Biomarkers evaluated covered a wide range of molecules: acute phase reactants such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and fibrinogen; cytokines such as interleukin (IL)-6, IL-8, and TNF-α; molecules of cardiac origin such as brain natriuretic peptide (BNP); molecules involved in collagen formation such as matrix metalloproteinase (MMP)-9; and molecules involved in fatty acid processing such as adiponectin. The most commonly studied biomarker was CRP, followed by IL-6 and TNF-α (see [S5 Table](#pone.0158843.s006){ref-type="supplementary-material"}). The use of CRP as a biomarker was investigated in 28 studies, in which 26 of these reported a statistically significant increase in concentration during AECOPD versus stable COPD and/or healthy controls. The CRP assays used were highly variable; five studies used an immunonephelometric assay, four studies used an immunoturbidimetric assay, and three studies used an immune latex agglutination assay. Despite these differences in techniques, the reported CRP results were congruent with each other. IL-6 was investigated in 18 studies, in which 13 showed significant increases during AECOPD versus stable COPD. Three studies also reported increased IL-6 levels during AECOPD, but the statistical analysis was either non-significant or not reported. TNF-α was investigated in ten studies, but with variable statistical significance. Seven out of ten studies reported significant increases in TNF-α concentrations during AECOPD compared to stable COPD, whereas two did not show statistical significance and one showed borderline statistical significance. Nevertheless, TNF-α concentrations were numerically higher in AECOPD compared with stable COPD or healthy controls. The measurement methods used for both IL-6 and TNF-α were all immuno-based assays, such as enzyme-linked immunosorbent assay (ELISA).

51 biomarkers that were investigated only in a single study are detailed in [S6 Table](#pone.0158843.s007){ref-type="supplementary-material"} along with statistical comparisons. Approximately half of these biomarkers were reported with an increased concentration during AECOPD, and the other half reported the opposite. 18 of these biomarkers were not statistically different between levels during AECOPD versus stable state.

Study quality assessment {#sec010}
------------------------

Out of the 59 articles, only 12 (20%) reported an ROC analysis (see [Table 2](#pone.0158843.t002){ref-type="table"}). Eight of the 12 studies used an ROC analysis to characterize biomarker performance in the diagnosis of AECOPD. Two studies performed ROC analyses to characterize biomarker performance in predicting AECOPD mortality. One study used the ROC to determine which patients would require antibiotics and one study to discriminate between mild, moderate, and severe AECOPD. The articles had a median mREMARK score of 13/20 with a range from 6 to 18/20; the detailed breakdown of the scores is tabulated in [S7 Table](#pone.0158843.s008){ref-type="supplementary-material"}. Only one article (2%), by Bafadhel et al, utilized a second, independent cohort to replicate biomarker performance \[[@pone.0158843.ref013]\]. This study, which had the highest mREMARK score at 18, included 145 AECOPD patients, and used a combination of serum biomarkers and sputum biomarkers to classify patients into four distinct exacerbation phenotype clusters \[[@pone.0158843.ref013]\]. CRP, CXCL10 and peripheral eosinophil counts were found to be useful in distinguishing between bacterial-, virus-, and eosinophil-associated exacerbations, respectively. The AUC results were 0.65 (Confidence Interval (CI): 0.57--0.74) for CRP, 0.76 (CI: 0.67--0.86) for CXCL10, and 0.85 (CI: 0.78--0.93) for peripheral eosinophil count. Findings of bacterial-associated exacerbations via CRP were replicated with a comparable AUC of 0.70 (CI: 0.59--0.82). In addition, findings of virus-associated exacerbations via CXCL10 were also replicated with a comparable AUC of 0.65 (CI: 0.52--0.78).

10.1371/journal.pone.0158843.t002

###### Selected publications from the review with Biomarker ROC analysis performance.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Reference**                                       **Sample Size**                   **Biomarker**    AUC (95% CI)[\*](#t002fn001){ref-type="table-fn"}   **Replication**   **ROC Use**                                                                            **mREMARK Score (/20)**
  --------------------------------------------------- --------------------------------- ---------------- --------------------------------------------------- ----------------- -------------------------------------------------------------------------------------- -------------------------
  Bafadhel M., et al. \[[@pone.0158843.ref013]\]      145 COPD                          CRP              1\) 0.65 (0.57--0.74)\                              External          1\) Discriminate bacterial AECOPD cluster\                                             18
                                                                                                         4) 0.73 (0.61--0.85)                                                  2) Discriminate viral AECOPD cluster\                                                  
                                                                                                                                                                               3) ROC for eosinophil associated exacerbations\                                        
                                                                                                                                                                               4) Validation performance                                                              

  IL-6                                                1\) 0.67 (0.58--0.76)                                                                                                                                                                                           

  Serum Amyloid-A                                     1\) 0.67 (0.58--0.76)                                                                                                                                                                                           

  TNFR1                                               1\) 0.62 (0.53--0.71)                                                                                                                                                                                           

  TNFR2                                               1\) 0.60 (0.50--0.70)                                                                                                                                                                                           

  CXCL10                                              2\) 0.76 (0.67--0.86)\                                                                                                                                                                                          
                                                      4) 0.65 (0.52--0.78)                                                                                                                                                                                            

  CXCL11                                              2\) 0.67 (0.56--0.78)                                                                                                                                                                                           

  IFNγ                                                2\) 0.65 (0.54--0.75)                                                                                                                                                                                           

  Peripheral Eosinophil %                             3\) 0.85 (0.78--0.93)                                                                                                                                                                                           

  IL-5                                                3\) 0.65 (0.55--0.76)                                                                                                                                                                                           

  CCL17                                               3\) 0.63 (0.53--0.73)                                                                                                                                                                                           

  Lacoma, A., et al. \[[@pone.0158843.ref060]\]       • 217 AECOPD\                     CRP              1\) 0.53 (0.72--1.61)\                              None              1\) Discriminate bacterial AECOPD\                                                     16
                                                      • 46 Stable COPD                                   2) 0.68 (0.65--1.76)                                                  2) Discriminate bacterial AECOPD with clinical symptoms                                

  Procalcitonin                                       1\) 0.52 (0.71--1.38)\                                                                                                                                                                                          
                                                      2) 0.66 (0.65--1.42)                                                                                                                                                                                            

  Neopterin                                           1\) 0.61 (0.39--0.90)\                                                                                                                                                                                          
                                                      2) 0.70 (0.31--0.87)                                                                                                                                                                                            

  Stolz, D., et al. \[[@pone.0158843.ref069]\]        208 AECOPD                        BNP              1\) 0.55 (0.41--0.68)\                              None              1\) Discriminate 6-month mortality\                                                    15
                                                                                                         2) 0.56 (0.45--0.66)                                                  2) Discriminate 2-year mortality                                                       

  Jin, Q., et al. \[[@pone.0158843.ref040]\]          64 AECOPD                         RBP4             0.88 (0.78--0.94)                                   None              Discriminate AECOPD patient mortality                                                  15

  Hurst, J.R., et al. \[[@pone.0158843.ref073]\]      90 AECOPD                         CRP only         1\) 0.66--0.80)\                                    None              1\) Discriminate AECOPD versus Stable COPD\                                            14
                                                                                                         2) 0.88 (0.82--0.93)                                                  2) Discriminate AECOPD with CRP and one major symptom versus Stable COPD               

  CRP, MMP-9, and MPIF-1                              1\) 0.75 (0.67--0.82)                                                                                                                                                                                           

  All 36 biomarkers                                   1\) 0.79 (0.73--0.86)                                                                                                                                                                                           

  Gumus, A., et al. \[[@pone.0158843.ref020]\]        43 AECOPD                         suPAR            0.81 (0.72--0.90)                                   None              Discriminate AECOPD on day 1 versus day 7                                              13

  Fibrinogen                                          0.76 (0.66--0.86)                                                                                                                                                                                               

  CRP                                                 0.70 (0.58--0.81)                                                                                                                                                                                               

  Shakoori, T.A., et al. \[[@pone.0158843.ref067]\]   • 13 AECOPD•\                     SP-D             1\) 0.76 (0.60--0.92)\                              None              1\) Discriminate AECOPD versus stable COPD and Controls\                               13
                                                      14 Stable COPD•\                                   2) 0.68 (0.48--0.89)                                                  2) Discriminate AECOPD versus stable COPD                                              
                                                      54 Controls                                                                                                                                                                                                     

  Falsey, A.R., et al. \[[@pone.0158843.ref047]\]     • 184 AECOPD•\                    Procalcitonin    1\) 0.76 (0.68--0.84)\                              None              1\) Discriminate AECOPD versus pneumonia patients at day 1\                            12
                                                      56 Pneumonia•\                                     2) 0.75 (0.67--0.82)\                                                 2) Discriminate AECOPD versus pneumonia patients at day 2\                             
                                                      16 Bacterial and viral AECOPD•\                    3) 0.70 (0.53--0.87)                                                  3) Discriminate bacterial and viral AECOPD versus viral AECOPD alone                   
                                                      25 viral AECOPD                                                                                                                                                                                                 

  Quint, J.K., et al. \[[@pone.0158843.ref064]\]      72 AECOPD                         IP-10 (CXCL10)   1\) 0.78 (0.65--0.91)\                              None              1\) Discriminate HRV-positive AECOPD versus HRV-negative AECOPD\                       11
                                                                                                         2) 0.82 (0.74--0.90)                                                  2) Discriminate HRV-positive AECOPD with coryzal symptoms versus HRV-negative AECOPD   

  Pazarli, A.C., et al. \[[@pone.0158843.ref054]\]    • 68 AECOPD•\                     Procalcitonin    1\) 0.89 (0.80--0.97)\                              None              1\) Discriminate mild versus moderate/severe exacerbation\                             10
                                                      50 Stable COPD                                     2) 0.89 (0.82--0.97)                                                  2) Discriminate patients with NPPV versus without                                      

  Phua, J., et al. \[[@pone.0158843.ref074]\]         • 43 COPD•\                       sTREM-1          0.77 (0.70--0.84)                                   None              Discriminate patients requiring antibiotics versus those that do not                   10
                                                      72 Pneumonia•\                                                                                                                                                                                                  
                                                      35 Asthma•\                                                                                                                                                                                                     
                                                      63 Controls                                                                                                                                                                                                     

  Adnan, A.M., et al. \[[@pone.0158843.ref037]\]      • 35 AECOPD•\                     Eotaxin          1\) 0.70\                                           None              1\) Discriminate AECOPD versus stable COPD\                                            6
                                                      30 Stable COPD•\                                   2) 0.87                                                               2) Discriminate Stable COPD versus Controls                                            
                                                      23 Controls                                                                                                                                                                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* AUC provided for the specific ROC use.

Selected studies from the review that contained biomarker characteristics and ROC performances. Only studies that performed an ROC analysis were included in this table and those without a biomarker ROC analysis were not included. REMARK scores are assigned based on whether the studies met the 20 reporting recommendations. The table is arranged in descending order based on the REMARK scores. Abbreviations: AUC = area under the curve, CCL = chemokine C-C motif ligand, CI = confidence interval, CXCL = chemokine C-X-C motif ligand, ECP = eosinophil cationic protein, FE = frequent exacerbators, HRV = human rhinovirus, ICU = intensive care unit, IFN = interferon, IL = interleukin, IP = interferon-γ inducible protein, LVD = left ventricular dysfunction, MMP-9 = matrix metallopeptidase-9, MPIF-1 = myeloid progenitor inhibitory factor-1, N/A = not available, NPPV = non-invasive positive pressure ventilation, RBP = retinol-binding protein, REMARK = recommendations for tumor marker prognostic studies, ROC = receiver-operator characteristics, Sens = sensitivity, Spec = specificity, SP-D = surfactant protein-D, TNFR = tumor necrosis factor receptor.

Discussion {#sec011}
==========

Ideally, a clinically useful biomarker, whether for AECOPD or other diseases, should consistently and accurately reflect disease activity. The test should perform similarly in a variety of COPD patients and cohorts, while inflicting the least invasiveness on a patient. In this systematic review, we have identified 59 studies that have prospectively evaluated a wide range of blood-based biomarkers in the diagnosis of AECOPD; however, we found a number of deficiencies in the literature that have likely impeded the translation of these biomarkers into widespread clinical use. Very few of these studies reported performance of their biomarkers using an ROC analysis and even fewer replicated their findings in an external cohort. Along these lines, many biomarkers have only been tested in single centres, again raising the necessity for validation of these results. Moreover, the definitions employed for AECOPD and stable states were inconsistent across studies, making it difficult to assess overall biomarker performance. Until these gaps in the literature are addressed, a biomarker that can accurately and consistently diagnose AECOPD may be challenging to achieve. The best studied biomarkers to date have reflected inflammatory and cytokine pathways (CRP, IL-6, and TNF-α); however, of these, only CRP concentrations appeared to be consistently elevated in the AECOPD state compared to convalescence. Still, only four studies evaluating CRP used an ROC analysis and only one study employed a second validation cohort.

Given these discrepancies in the literature, minimum standard criteria implemented for every biomarker study may help to strengthen the quality of biomarker research. Currently, there is no standardized method of assessing the quality of COPD biomarker performance \[[@pone.0158843.ref017]\]. We propose here the use of the modified REMARK (mREMARK) score, derived from the oncology literature to better serve COPD. In the field of oncology, REMARK guidelines for biomarker studies have been in place since 2005 to facilitate the translation of biomarkers from discovery to clinical trials \[[@pone.0158843.ref018]\]. These detailed and rigorous criteria help to provide a realistic and reproducible performance assessment and importantly include the requirement that studies report estimated effects of biomarkers, validation, comparisons to standard prognostic variables, and transparent statistical methods. Although the REMARK checklist was originally developed to assess the quality of biomarker studies in oncology, we believe that with minimal modifications ("tumor" being replaced by "AECOPD" and standard tumor prognostic tools being replaced by lung function measurements), it may serve as an assessment tool in COPD exacerbation biomarker discovery. In accordance with mREMARK guidelines, very few among the selected studies in this systematic review would be deemed of "good" quality.

In addition to the mREMARK criteria, we recommend the use of ROC analyses and AUC statistics to objectively evaluate biomarker performance \[[@pone.0158843.ref077]\]. Such analyses confer distinct advantages over individual measures of sensitivity and specificity, and certainly over simple t-test statistics calculating significance between case and control biomarker levels (which can be falsely reassuring with a large enough sample size). For one, ROC analyses allow for an unbiased assessment of the best cut-off point for biomarker levels \[[@pone.0158843.ref078],[@pone.0158843.ref079]\]. Second, the AUC statistic considers both sensitivity and specificity in reporting a test's discriminative power, without regard to the prevalence of disease in specific populations \[[@pone.0158843.ref078],[@pone.0158843.ref080]\]. It further allows an objective comparison of biomarker performance across studies and platforms whereby a biomarker with an AUC \>0.85 is considered to have high accuracy while a biomarker with an AUC between 0.7 and 0.85 has borderline potential for clinical translation and warrants further refinement and validation. \[[@pone.0158843.ref017],[@pone.0158843.ref081]\].

Furthermore, even in the 12 studies that reported an ROC analysis (some with remarkable AUC values), caution must be exercised when interpreting the results. The vast majority of these studies performed statistical analyses on discovery cohorts only without reproducing the performance in an external cohort. These studies run the risk of over-fitting their statistical model to the initial discovery cohort, particularly if the discovery cohort is small in size, and often times these initially optimistic findings may perform poorly in a new cohort. Data sharing across large cohorts has been proposed as one mechanism to counteract this obstacle \[[@pone.0158843.ref082]\], but in the absence of available external cohorts, methods such as cross-validation may provide an additional degree of validation and thus confidence that the results could be replicated in wider use. In this approach, the statistical model is applied to successive data sets in which one or more samples have been removed, and tested on the left out sample(s); the cross-validation AUC is therefore an estimate of the model's discriminative power in the samples used. Types of cross-validation include leave-one-out cross-validation, *k-*fold cross-validation, and repeated random-split cross-validation. In leave-pair-out cross validation, a case and its corresponding control are left out in each iteration of the cross-validation \[[@pone.0158843.ref083],[@pone.0158843.ref084]\]. In *k-*fold cross-validation, data are split into *k* subsets of equal size, with each one serving as the test set and the remaining *k*-1 subsets serving as the training set in successive iterations. In repeated random-split cross-validation, data are split into test and training sets randomly and repeatedly \[[@pone.0158843.ref084]\]. Given the risk of overly optimistic results with standard AUC statistics, we suggest that all future biomarker studies employ these cross-validation techniques, even in studies with available external validation cohorts.

There were a few limitations with our systematic review. First, the decision to use the mREMARK checklist to rank the selected studies in our review was arbitrary, as alluded to previously, but one made based on the fact that there are no alternative ranking methods for biomarker studies in COPD exacerbations. Nevertheless, the ranking scores via the mREMARK guidelines were objective measures and provided some guidance as to how to judge the quality of biomarker studies. Second, given the heterogeneity of biomarkers studied, we were not able to perform a meta-analysis on the results. However, we summarized the top three most studied biomarkers and their respective statistical significance to provide an overview. Last, we recognize there could be some potential publication bias, due to the fact that negative studies tend to be less published than positive studies.

In summary, while we found a number of studies that have evaluated potential candidate biomarkers for AECOPD diagnosis, we also identified a number of deficiencies in the COPD biomarker literature that make it difficult to fully evaluate the performance of these biomarkers. Standardized guidelines such as the mREMARK score and the use of ROC curves may help to streamline biomarker performance reporting, while external validation or at least internal cross-validation techniques may help instil confidence that biomarkers can be translated successfully into the real-world clinical realm. In future, the study of biomarkers in COPD exacerbations should not only encompass these principles, but also incorporate stringent and consistent definitions of an exacerbation. Collection of blood samples prior to the initiation of therapies and at multiple longitudinal time points following an exacerbation are also necessary to prevent possible confounding by medications and to characterize the activity of the biomarker along the time course of disease. Only then can the field progress towards a working biomarker in COPD.
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